Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy - A propensity analysis

被引:74
作者
Grzybowski, M
Clements, EA
Parsons, L
Welch, R
Tintinalli, AT
Ross, MA
Zalenski, RJ
机构
[1] Wayne State Univ, Sch Med, Dept Emergency Med, Ctr Healthcare Effectiveness, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Dept Med, Div Cardiol, Detroit, MI 48201 USA
[3] Spectrum Hlth Hosp, Dept Pharm, Grand Rapids, MI USA
[4] Ovat Res Grp, Chicago, IL USA
[5] William Beaumont Hosp, Dept Emergency Med, Royal Oak, MI 48072 USA
[6] John D Dingell Vet Affairs Hosp, Dept Med, Sect Urgent Care, Detroit, MI USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2003年 / 290卷 / 14期
关键词
D O I
10.1001/jama.290.14.1891
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context There are no definitive recommendations for the management of acute myocardial infarction (AMI) in patients with ST-segment elevation who have contraindications to thrombolytic therapy. It is not clear whether, and the extent to which, immediate mechanical reperfusion (IMR) reduces in-hospital mortality in this population. Objective To determine whether IMR (defined as percutaneous coronary intervention or coronary artery bypass graft surgery) is associated with a mortality benefit in patients with acute ST-segment elevation AMI who are eligible for IMR but have contraindications to thrombolytic therapy. Design, Setting, and Patients From June 1994 to January 2003, the National Registry of Myocardial Infarction 2, 3, and 4 enrolled 1799704 patients with AMI. A total of 19917 patients with acute ST-segment elevation were eligible for IMR but had thrombolytic contraindications after excluding patients who were transferred in from or out to other facilities, patients who received intracoronary thrombolytics, and those who received no medications within 24 hours of arrival. Main Outcome Measure In-hospital mortality. Results Of the 19917 patients, 4705 patients (23.6%) received IMR and 5173 patients (25.9%) died. In-hospital mortality rates in the IMR and non-IMR treated groups in the unadjusted analysis were 11.1%, representing 521 of 4705 patients, and 30.6%, representing 4652 of 15212 patients, respectively, for a risk reduction of 63.7% (odds ratio [OR], 0.28; 95% confidence interval [CI], 0.26-0.31). In a further analysis using a propensity matching score to reduce the effects of bias, 3905 patients who received IMR remained at lower risk for in-hospital mortality than 3905 matched patients (10.9% vs 20.1%, respectively, for a risk reduction of 45.8%; OR, 0.48; 95% Cl, 0.43-0.55). Following a second logistic model applied to the matched groups to adjust for residual differences, a significant treatment effect persisted (OR, 0.64; 95% Cl, 0.56-0.75). Conclusions In this population, IMR was associated with a reduced risk of in-hospital mortality after appropriate adjustments. Of those we studied who were eligible for IMR, 15212 patients (76.4%) did not receive it. These results suggest that using IMR in patients with acute ST-segment elevation AMI and contrainclications to thrombolytics should be strongly considered.
引用
收藏
页码:1891 / 1898
页数:8
相关论文
共 29 条
  • [11] Joffe MM, 1999, AM J EPIDEMIOL, V150, P327
  • [12] Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials
    Keeley, EC
    Boura, JA
    Grines, CL
    [J]. LANCET, 2003, 361 (9351) : 13 - 20
  • [13] Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy
    Magid, DJ
    Calonge, BN
    Rumsfeld, JS
    Canto, JG
    Frederick, PD
    Every, NR
    Barron, HV
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (24): : 3131 - 3138
  • [14] A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy - Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial
    McCullough, PA
    O'Neill, WW
    Graham, M
    Stomel, RJ
    Rogers, F
    David, S
    Farhat, A
    Kazlauskaite, R
    Al-Zagoum, M
    Grines, CL
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (03) : 596 - 605
  • [15] DANAMI-2: Is primary angioplasty superior to thrombolysis in acute MI when the patient has to be transferred to an invasive centre?
    Moon, JCC
    Kalra, PR
    Coats, AJS
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 85 (2-3) : 199 - 201
  • [16] MOSES LE, 1995, MED CARE, V33, pAS8
  • [17] Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: A matched analysis using propensity scores
    Normand, SLT
    Landrum, NB
    Guadagnoli, E
    Ayanian, JZ
    Ryan, TJ
    Cleary, PD
    McNeil, BJ
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2001, 54 (04) : 387 - 398
  • [18] Parsons L.S., 2001, P 26 ANN SAS USERS G
  • [19] Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction - Observations from the national registry of myocardial infarction 4
    Peterson, ED
    Pollack, CV
    Roe, MT
    Parsons, LS
    Littrell, KA
    Canto, JG
    Barron, HV
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (01) : 45 - 53
  • [20] TREATMENT OF MYOCARDIAL-INFARCTION IN THE UNITED-STATES (1990 TO 1993) - OBSERVATIONS FROM THE NATIONAL REGISTRY OF MYOCARDIAL-INFARCTION
    ROGERS, WJ
    BOWLBY, LJ
    CHANDRA, NC
    FRENCH, WJ
    GORE, JM
    LAMBREW, CT
    RUBISON, RM
    TIEFENBRUNN, AJ
    WEAVER, WD
    [J]. CIRCULATION, 1994, 90 (04) : 2103 - 2114